Table 1 Baseline characteristics of the study subjects according to the TG/HDL-C ratio

Age, years

60 (50–69)

59 (51–68)

61 (51–70)

57 (49–65)

0.3249

Female sex, %

26.8

28.2

28.2

24.1

0.7819

DM, %

32.3

28.2

31.8

36.8

0.4837

Dialysis vintage, years

9.4 (4.7–15.8)

11.1 (5.7–16.3)

10.8 (4.4–16.9)

8.0 (4.6–13.8)

0.2608

History of hypertension, %

79.7

80.0

76.5

82.6

0.6107

History of previous CVD, %

29.2

23.5

35.3

28.7

0.2394

Systolic BP, mmHg

153 (139–165)

154 (142–165)

152 (138–166)

153 (136–163)

0.7112

Diastolic BP, mmHg

82 (73–91)

83 (76–91)

81 (72–90)

82 (70–93)

0.4152

BMI, kg/m²

21.8 (19.7–24.4)

20.5 (19.0–22.6)

21.8 (19.7–24.0)

23.2 (21.1–25.7)

<0.0001

 Hemoglobin, g/dL

10.7 (10.2–11.2)

10.7 (10.2–11.1)

10.6 (10.1–11.2)

10.8 (10.1–11.4)

0.2499

 Creatinine, mg/dL

11.8 (10.3–13.5)

11.4 (10.15–12.75)

12.0 (10.15–13.65)

12.3 (10.4–13.9)

0.1032

 Calcium (Ca), mg/dL; corrected

9.0 (8.6–9.4)

9.0 (8.6–9.4)

9.1 (8.45–9.4)

9.0 (8.6–9.4)

0.9831

 Phosphorus (P), mg/dL

5.4 (4.6–6.1)

5.5 (4.8–6.2)

5.1 (4.4–5.9)

5.5 (4.5–6.1)

0.0967

 Ca x P, (mg/dL)²

48.1 (40.9–55.2)

51.4 (42.1–55.7)

45.6 (40–54.1)

47.8 (41.2–57)

0.0554

 Whole PTH, pg/mL

63 (31–103)

68 (28–95)

53 (27–110)

64 (34–114)

0.5728

 CRP, mg/L

0.1 (0.1–0.3)

0.1 (0.1–0.2)

0.1 (0.1–0.3)

0.1 (0.1–0.4)

0.1403

 Albumin, g/L

3.9 (3.7–4.1)

3.9 (3.7–4.1)

3.9 (3.7–4.1)

3.9 (3.7–4.1)

0.9530

 T-CHO, mg/dL

157 (137–178)

156 (136–177)

150 (133–170)

162 (142–188)

0.0341

 TG, mg/dL

98 (70–144)

60 (47–73)

98 (83–112)

172 (138–229)

<0.0001

 HDL-C, md/dL

44 (37–55)

59 (51–72)

43 (40–49)

37 (31–41)

<0.0001

 LDL-C, mg/dL

77 (62–94)

69 (54–86)

79 (65–103)

86 (64–105)

0.0001

 TG/HDL-C ratio

2.28 (1.29–3.66)

1.03 (0.76–1.29)

2.27 (1.84–2.61)

4.63 (3.62–6.57)

<0.0001

 ESA

92.5

91.5

90.5

95.4

0.4447

 HMG-CoA reductase inhibitors

29.4

22.9

24.7

40.5

0.0228

 Antihypertensive agents

79.0

77.7

78.8

80.5

0.9017